Biopharma

Gabe Cavazos is a Senior Managing Director in Investment Banking at Leerink Partners.

Gabe joined Leerink Partners in 2008 from J.P. Morgan where he was a member of the Mergers & Acquisitions group in the New York office. He covers East Coast and European biopharma companies and has 15+ years of transaction experience, including more than 100 transactions across M&A advisory, equity and equity linked financings. Prior to J.P. Morgan, he spent eight years in the pharmaceutical industry at Merck and Pfizer.

He earned his M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. from The University of Michigan.

Jon Civitarese is a Senior Managing Director in Investment Banking at Leerink Partners.

Jon was one of the Firm’s earliest employees when he joined in 1995, providing advisory services to high-net-worth individuals in the Private Client Group prior to moving to Investment Banking. Since 1999, his activities have included advising public and private life science companies on strategic initiatives and equity capital financings as part of the Firm’s investment banking team. In addition to his primary banking responsibilities, he has also served as a senior member of the equity capital markets and syndicate team since 2001.

He began his career by serving in the U.S. Army as an infantry soldier, and later graduated from the University of Maine.

Murphy Gallagher is a Senior Managing Director in Investment Banking at Leerink Partners.

Murphy focuses on the Biopharma sector and has over 17 years advising companies on capital markets, mergers and acquisitions and strategic advisory assignments. He is based in San Francisco and focuses on companies in western North America and the Asia Pacific region. He joined the firm in 2009 and prior to that was at Merrill Lynch, where he was a member of the Global Healthcare Investment Banking Group.

He earned a B.A. from Georgetown University.

Andrew Gitkin is a Senior Managing Director in Investment Banking at Leerink Partners.

Andrew joined the Firm in 2024 from Raymond James & Associates where he most recently served as a Senior Managing Director and Vice Chairman in the healthcare investment banking group. He brings over 25 years of healthcare-focused experience specializing in the biopharma and medical device sectors, including more than 100 transactions across M&A advisory, equity and equity linked financings. Prior to Raymond James, he served as a Managing Director and Head of West Coast Biotechnology at PiperJaffray & Company, and Senior Vice President at Moelis & Company. Andrew’s previous experience also includes roles as a Vice President of Tavistock Life Sciences and leading a biotechnology start-up. He started his career in the Equity Research Departments of SalomonSmithBarney and UBS.

He is a member of the UCLA Health System Board, and he earned his BBA from Emory University.

Dr. Anurag Jindal is a Senior Managing Director in Investment Banking at Leerink Partners covering the biopharma sector. He has over two decades of experience in the biopharma industry, as an investment banker, a consultant, and in strategic roles at a major pharmaceutical company.

Prior to joining Leerink Partners in 2021, Anurag was a Managing Director in the Healthcare Investment Banking group at Bank of America where he focused on strategic advisory and capital markets transactions for public and private companies in the biotech sector. Previously to his work at Bank of America, Anurag was the Deputy Head of Pharma M&A and in the Pharma Strategy Group at Novartis in Switzerland and in the Healthcare Investment Banking group at JP Morgan in both New York and San Francisco. He started his career as a Pharmaceutical Analyst at Health IQ in Los Angeles.

He holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley and a M.D. from the University of Southern California.

Sean Pitt is a Senior Managing Director in Investment Banking at Leerink Partners.

Sean has over a decade of healthcare investment banking experience and joined Leerink Partners in 2017. He has advised a broad range of biopharma companies across equity and strategic advisory assignments and transactions, having worked on over 200 transactions during his career.

He earned a B.S. from The University of Sydney, Australia.

Byron Webster is a Senior Managing Director in Investment Banking at Leerink Partners and is focused on the Specialty Pharmaceuticals sector. He has over 16 years of experience advising pharmaceutical companies on M&A, private and public financing assignments.

Prior to joining the Firm in 2015, Byron worked at Lazard where he was a Vice President in the Healthcare Group. Prior to Lazard, he began his career at Wells Fargo Securities.

He earned a B.A. summa cum laude from Wake Forest University.

Andrew Berens, M.D., is a Senior Research Analyst at Leerink Partners covering Targeted Oncology.

Prior to joining the Firm in 2018, Andrew was an Executive Director and Senior Biotechnology Research Analyst at Morgan Stanley focusing on mid- and small-cap biotechnology companies. He practiced as an emergency medicine physician for a decade before starting his career in equity research. He also worked in the pharma industry at Ikaria Pharmaceuticals, where he was a Senior Director in business development, leading search and development efforts.

In 2017 he was named a Runner Up in Institutional Investor’s 2017 All–America Research Team for Biotechnology/Mid- & Small-Cap.

He earned M.B.A. degrees from Columbia Business School and London Business School, his M.D. from Emory University, and an undergraduate degree in English Literature from Tulane University.

Jonathan Chang, Ph.D., CFA is a Senior Research Analyst at Leerink Partners covering Emerging Oncology. He has been an important contributor to the Firm’s biotechnology research product and insights.

Jonathan joined the Firm in 2013 as an Associate supporting the Firm’s senior oncology biotechnology research team and in 2016, he assumed research coverage of several important emerging biotechnology companies. In 2018, he was named a Rising Star in Institutional Investor’s 2018 All-America Research Team for Biotechnology/Mid- & Small-Cap.

He earned a Ph.D. in Pharmacology from Cornell University, an M.A. in Biotechnology from Columbia University, and an Honors B.Sc. in Genes, Genetics, and Biotechnology from the University of Toronto. Dr. Chang is a CFA charter holder.

Mani Foroohar, M.D., is a Senior Research Analyst within our Therapeutics team focusing on Genetic Medicines.

Mani joined Leerink Partners from Aptigon Capital, a Citadel Company, where he most recently was a Therapeutics Analyst focused on U.S. and EU biotechnology, major pharmaceuticals and specialty pharmaceuticals sectors. Prior to Aptigon, he was an Analyst at Green Owl Capital Management and an Assistant Vice President of Equity Research at Barclays. In 2013, Mani co-founded Cellanyx Diagnostics, a company developing a proprietary live tumor cell, phenotypic platform for precision risk stratification in cancer to inform clinical treatment decision-making.

He holds an M.D. from Stanford, where he was a Howard Hughes Medical Institute Research Fellow in the Department of Genetics, an M.B.A. from Columbia, and a B.S. from UCLA.

Marc Goodman is a Senior Research Analyst at Leerink Partners covering Neuroscience and Ophthalmology.

Prior to joining the Firm in 2018, Marc was most recently a Managing Director and U.S. Healthcare Analyst at UBS Investment Bank, where he focused on large-cap and specialty pharmaceuticals sectors. Prior to UBS, he covered specialty pharmaceuticals and generics sectors for over 15 years as a Managing Director at Crédit Suisse AG and as an Executive Director at Morgan Stanley.

Marc has been ranked by Institutional Investor as a top analyst in Specialty Pharmaceuticals for well over a decade and has also expanded his coverage and interests into global and emerging biopharmaceutical companies in recent years.

He earned his MBA from The Ohio State University and his B.A. in Economics from Tufts University.

Daina Graybosch, Ph.D., is a Senior Research Analyst at Leerink Partners covering Immuno-Oncology.

Prior to joining the Firm in 2018, Daina worked at McKinsey & Company as a Senior Expert and Head of McKinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center. In these roles, she developed several McKinsey solutions that bring data and advanced analytics to pharmaceutical development decisions. In her 11 years at McKinsey, she developed a rich understanding of oncology through her work with companies across the value chain, including Pharmaceutical, Diagnostic, Academic Medical Center, and Genomic/Data.

She earned a Ph.D. in Chemistry and Chemical Biology from Harvard University and dual B.S. degrees in Biology and Chemistry from the University of Utah.

Roanna Ruiz, Ph.D., is a Senior Research Analyst at Leerink Partners covering Biopharma / Cardiovascular, Endocrine Disorders & Infectious Disease. She excels in quality of research, depth of insights and understanding, and the service provided to the Firm’s internal and external clients. Prior to covering the IDECV sectors, she was a core member of Leerink Partners’ Neuroscience team helping to deliver science-forward and deep-dive fundamental research to clients.

Roanna joined the Firm in 2018 after holding equity research roles at UBS and H.C. Wainwright. Previously, Roanna spent two years in pharmaceutical industry consulting at IQVIA working on M&A, product launch strategy, and pricing & reimbursement projects.

She earned a Ph.D. in Biomedical Engineering from Cornell University, and a B.S. in Engineering Sciences from Harvard University.

Joseph Schwartz is a Senior Research Analyst at Leerink Partners covering Rare Diseases.

Prior to joining the Firm in 2003, Joseph provided economic and strategic consulting services to biotechnology and pharmaceutical companies with Charles River Associates. Earlier in his career, he held equity research positions at SG Cowen, State Street Research, and J.P. Morgan, where he analyzed the fundamental performance drivers of investments in the health care, retail, consumer, media, and entertainment sectors.

He was named #1 Stock Picker for Pharmaceuticals in the 2011 FT/StarMine Analyst Awards. In 2010, he earned the Wall Street Journal’s #1 ranking for biotech stock picking as part of its “Best on the Street” analysts survey, which topped his #2 ranking in the Journal’s 2008 “Best on the Street” rankings.

He earned an M.B.A. from Babson College and a B.A. in Economics from Colby College.

Thomas J. Smith is a Senior Research Analyst at Leerink Partners covering Immunology and Metabolism. Prior to covering the Immunology and Metabolism sector, Thomas was a key member of Leerink Partners’ Targeted Oncology team helping to deliver in-depth fundamental research to clients.

Prior to joining the Firm in 2018, Thomas was most recently a Vice President and Research Analyst at Morgan Stanley, covering leading and emerging biopharmaceutical companies across numerous therapeutic areas, including oncology, NASH, and lead coverage of women’s health companies. Prior to that, he worked at FBR Capital Markets on the biotechnology team, responsible for coverage of large, mid- and small-cap companies. Thomas began his career at Bloomberg, where he held roles of increasing responsibility, including coverage of the biotech and specialty pharmaceutical sectors for Bloomberg Intelligence.

He earned his B.S. in Finance and Psychology from The College of New Jersey.

Dan Dubin, M.D., is the Vice Chairman, Global Co-Head of Investment Banking and Global Co-Head of Healthcare Investment Banking at Leerink Partners and sits on the Firm’s executive committee.

For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients.  In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Caroline Cameron is the Chief Operating Officer of Investment Banking at Leerink Partners.

Prior to joining the Firm in 2024, Caroline was the Chief Operating Officer at Keefe, Bruyette & Woods (KBW, A Stifel Company). Prior to her time at Keefe, Bruyette & Woods, she worked in investment banking at Edgeview Partners (acquired by Piper Jaffrey), and as a research analyst at Fox-Pitt, Kelton and Macquarie Capital.

She earned a B.A. in Psychology and Economics from Hamilton College where she graduated Phi Beta Kappa.

Jim Kelly is a Senior Managing Director, Director of Research at Leerink Partners. Mr. Kelly is responsible for product management, analyst development and equity strategy.

Prior to joining Leerink Partners in 2015, Mr. Kelly worked at Credit Suisse, where he served in research management as an Associate Director of Equity Research in New York and was responsible for leading key, strategic initiatives in research product and process development. Prior to his ADOR role at Credit Suisse, Mr. Kelly spent 13 years in Equity Research covering the US Pharmaceuticals industry for Lehman Brothers, Goldman Sachs and Credit Suisse First Boston.

Mr. Kelly received his M.B.A. from Columbia Business School and earned his B.S. in Mechanical Engineering from Lehigh University.  Mr. Kelly also serves on the board of the Lehigh Business School Dean’s Advisory Council.

Julia Belladonna is a Managing Director, Associate Director of Research at Leerink Partners.

Julia joined the Firm in 2021 from Credit Suisse where she spent 20+ years in a variety of roles, most recently as the COO of Global Economics for their Institutional client & Private Wealth Management businesses. She brings over two decades of experience in financial markets, business and talent management, international regulatory requirements, and operations. She has excelled in managing complex groups, collaborating across business units, and developing strategies to deliver research to clients. Prior to Credit Suisse, she was an Industry Analyst at Merrill Lynch.

Julia earned a B.A. in Applied Mathematics and History from Williams College and an M.B.A. in Finance from Columbia Business School.